Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 8, 1996, Pages 17-25

  Ereshefsky, Larry ^a,b,c   Riesenman, Cara ^a,c   Lam, Y W Francis ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b San Antonio State Hospital   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CISAPRIDE; CLONAZEPAM; CLOZAPINE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; DEXTRORPHAN; DIAZEPAM; DICLOFENAC; DILTIAZEM; ENZYME INHIBITOR; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; KETOCONAZOLE; NEFAZODONE; PAROXETINE; PSEUDOEPHEDRINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRIAZOLAM; TRIAZOLOBENZODIAZEPINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SEROTONIN UPTAKE INHIBITORS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0029810908     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Krishna DR, Klotz U. Extrahepatic metabolism of drags in humans. Clin Pharmacokinet 1994;26:144-160
2. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-184
3. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51
4. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibition of desipramine hydroxylation in vitro by serotonin reuptake inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-1283
5. Geungerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986;30:287-295
6. Spina E, Birgerson C, von Bahr C, et al. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquin in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984;36:677-682
7. Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993;43:827-832
8. Skjelbo E, Brosen K, Hallas J, et al. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23
9. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993;3:197-204
10. Schmid B, Bircher J, Preisig R, et al. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38:618-624
11. Ereshefsky L, Anderson CB, True JE, et al. Plasma concentrations of oral risperidone and active metabolite in schizophrenics [abstract]. Pharmacotherapy 1993;13:292
12. Baumann P, Meyer JW, Amey M, et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992;14:1-8
13. Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51: 278-287
14. Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-409
15. Sindrup SH, Poulsen L, Brosen K, et al. Are poor metabolizers of sparteine/ debrisoquin less pain tolerant than extensive metabolizers? Pain 1993;53: 335-349
16. Lam YWF, Casto DT, Dunn JF. Drug metabolizing capacity in Mexican Americans [abstract]. Clin Pharmacol Ther 1991;49:159
17. Lam YWF, Rodriquez SY. High performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidative phenotyping by fluorescence and ultraviolet detection. Ther Drug Monit 1993;15: 300-304
18. Lam YWF, Rodriquez SY, Casto DT. No time-dependent change in cytochrome P450 2D6 phenotyping results during HPLC analysis. Clin Chem 1992;38:2350-2352
19. Ereshefsky L, Riesenman C, Lam F. Antidepressant drug interactions and the cytochrome P450 system: the role of CYP2D6. Clin Pharmacokinet 1995;29(suppl 1):10-19
20. Otton SV, Ball SE, Cheung SW, et al. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5-HT uptake inhibitors [abstract]. Clin Pharmacol Ther 1994;55:141
21. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin reuptake inhibitors on cytochrome P-450 2D6 activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265
22. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 1994;30:251-259
23. Brosen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolisers of sparteine. Eur J Clin Pharmacol 1993;44:349-355
24. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline and fluoxetine. J Clin Psychopharmacol 1994;14:90-98
25. Barbhaiya RH, Shukla UA, Greene DS, et al. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 1996;16:26-34
26. Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol 1994;14: 159-162
27. Llerena A, Alm C, Dahl M, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-97
28. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 1991;31:655-660
29. Goff DC, Midha KK, Brotman AW, et al. Elevation of plasma concentrations of haloperidol after addition of fluoxetine. Am J Psychiatry 1991; 148:790-792
30. Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol 1994;14: 159-162
31. Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry 1993;150:1125-1126
32. Kurtz DL, Bergstrom RF, Goldberg MJ, et al. Drug interaction between sertraline and desipramine or imipramine [abstract]. J Clin Pharmacol 1994;34:1030
33. Spina E, Pollicino AM, Avenoso A, et al. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993;15:243-246
34. Ereshefsky L, Riesenman CL, Lam FY. Comparative in vivo CYP 2D6 drug interaction potential of SSRIs [abstract]. Presented at the American College of Neuropsychopharmacology Annual Meeting; December 1995; Puerto Rico
35. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-248
36. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994;55(12, suppl):38-45
37. Perucca E, Gatti G, Cipolla C, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-476
38. Fluvoxamine. Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics; 1996:2544-2548
39. Brosen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P-450 1A2. Biochem Pharmacol 1993;45: 1211-1214
40. Riesenman CL. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995;15(suppl 6, pt 2): 84S-99S
41. von Moltke LL, Greenblatt DJ, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(suppl 1):33-44
42. Yun C, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos Biol Fate Chem 1992;21:403-409
43. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-1518
44. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-238
45. Richards DM, Brogden RN, Heel RC, et al. Astemizole: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1984;28:38-61
46. Goss JE, Ramo BW, Blake K. Torsades de pointes associated with astemizole (Hismanal) therapy [letter]. Arch Intern Med 1993;153:2705
47. Bran S, Murray WA, Hirsch IB, et al. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-768
48. Cisapride. Physicians' Desk Reference. 49th ed. Montvale, NJ: Medical Economics; 1995:1191-1193
49. Marchiando RJ, Cook MD, Jue SG. Probable terfenadine-fluoxetine-associated cardiac toxicity [letter]. Ann Pharmacother 1995;29:937-938
50. von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-131
51. Loratadine. Physicians' Desk Reference. 49th ed. Montvale, NJ: Medical Economics; 1995:2246-2247
52. Brannan MD, Reidenberg P, Radwanski E, et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995;58:269-278
53. Wright CE, Lasher-Sisson TA, Steenwyk RC, et al. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103-106
54. Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52:479-486
55. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-39
56. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 1994;56:601-607
57. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines, III: a pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 1995;15:399-408
58. Barbhaiya RH, Shukla UA, Kroboth PD, et al. Coadministration of nefazodone and benzodiazepines, II: a pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995;15:320-326
59. Nefazodone. Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics; 1996:771-775
60. Kroboth P, Folan M, Lush RM, et al. Coadministration of nefazodone and benzodiazepiaes, I: pharmacodynamic assessment. J Clin Psychopharmacol 1995;15:306-315
61. Sternbach H. Fluoxetine-associated potentiation of calcium-channel blockers. J Clin Psychopharmacol 1991;11:390-391
62. Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50:10-15
63. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994;47:1969-1979
64. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991;84:583-584
65. Spina E, Avenoso A, Pollicino AN, et al. Carbamazepine Coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993;15:247-250
66. Carrillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994;55:293-304
67. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53:503-514
68. Brosen K. Drug interactions and the cytochrome P450 system: the role of cytochrome P450 1A2. Clin Pharmacokinet 1995;29(suppl 1):20-25
69. Rasmussen BB, Maenpaa J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-159
70. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 1991;6:460-462
71. Tassaneeyakul W, Birkett DJ, Manus ME, et al. Caffeine metabolism by human hepatic cytochromes P450: contribution of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994;47:1767-1776
72. Brosen K. Drug interactions and CYP1A2. Presented at Solvay Pharmaceuticals' Experts Panel Meeting; December 1994; Boston, Mass
73. Jerling M, Lindström L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-374
74. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics l994;4:285-299
75. Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand 1989;80(suppl 350):102-106
76. De Clerck F. The role of serotonin in thrombogenesis. Clin Physiol Biochem 1990;8(suppl 3):40-49
77. Shader RI, Greenblatt DJ, von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994;14:375-376
78. Bertilsson L, Henthorn TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45: 348-355